Ikena And Inmagene Enter Merger Agreement; $175M To Support IMG-007 Development, Includes $75M Private Placement; Combined Company ImageneBio To Target Atopic Dermatitis; Expected Close Mid-2025 And Trade On Nasdaq Under The Ticker "IMA"
Ikena And Inmagene Enter Merger Agreement; $175M To Support IMG-007 Development, Includes $75M Private Placement; Combined Company ImageneBio To Target Atopic Dermatitis; Expected Close Mid-2025 And Trade On Nasdaq Under The Ticker "IMA"
Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function
Inmagene生物製藥是一家臨牀階段公司，專注於開發IMG-007，這是一種非耗竭性的抗OX40單克隆抗體，具有延長的半衰期和沉默的ADCC功能。
The transaction is expected to result in approximately $175 million to support further development of IMG-007, including $75 million from an oversubscribed Private Placement that will close immediately following the merger
該交易預計將導致大約17500萬美元的資金，以支持IMG-007的進一步開發，包括來自超額認購的定向增發的7500萬美元，該增發將於合併後立即完成。
The Financing includes both new investors such as Deep Track Capital, Foresite Capital, RTW Investments, and existing Ikena investors such as BVF Partners L.P., Blue Owl Healthcare Opportunities, Omega Funds, and OrbiMed
此次融資包括新的投資者，如Deep Track Capital、Foresite Capital、RTW Investments，以及現有Ikena投資者，如BVF Partners L.P.、Blue Owl Healthcare Opportunities、Omega Funds和OrbiMed。
The transaction is expected to close in mid-2025
該交易預計將在2025年中期完成。
BOSTON and SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena, "))) and Inmagene Biopharmaceuticals ("Inmagene") announced they have entered into a definitive merger agreement. In connection with the merger, Ikena has entered into subscription agreements for a $75 million private placement (the "Financing") with a syndicate that includes new investors such as Deep Track Capital, Foresite Capital, RTW Investments, and existing Ikena investors such as BVF Partners L.P., Blue Owl Healthcare Opportunities, Omega Funds, and OrbiMed. The combined company will focus on the development of IMG-007, a monoclonal antibody (mAb) targeting OX40, for the treatment of atopic dermatitis. The combined company plans to operate under the name "ImageneBio, Inc." ("ImageneBio") and trade on NASDAQ under the ticker "IMA".
波士頓和聖地亞哥，2024年12月23日（GLOBE NEWSWIRE）——Ikena Oncology, Inc.（納斯達克：IKNA，"Ikena，"）與Inmagene Biopharmaceuticals（"Inmagene"）宣佈他們已經簽訂了最終合併協議。與合併相關，Ikena已與包括Deep Track Capital、Foresite Capital、RTW Investments等新投資者，以及BVF Partners L.P.、Blue Owl Healthcare Opportunities、Omega Funds和OrbiMed等現有Ikena投資者簽訂了7500萬美元的認購協議（「融資」）。合併公司將專注於開發IMG-007，這是一種針對OX40的單克隆抗體（mAb），用於治療特應性皮炎。合併公司計劃以「ImageneBio, Inc.」（「ImageneBio」）的名義運營，並在納斯達克上市，股票代碼爲「IMA」。
譯文內容由第三人軟體翻譯。
